citric acid, iron, sorbitol drug combination profile

citric acid, iron, sorbitol drug combination: RN given refers to (D)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	20715017
SCHEMBL ID	60075
MeSH ID	M0051790

Synonym
iron sorbitol citrate
jectofer
iron sorbitex
astra 1572
hsdb 1967
62765-90-6
iron sorbitex [usan:usp]
yectofer
citric acid, iron, sorbitol drug combination
SCHEMBL60075
1338-16-5
DTXSID40928274
iron(3+) 2-hydroxypropane-1,2,3-tricarboxylate--hexitol (1/1/1)
iron sorbitex.
(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+)
iron-sorbitol

Excerpt	Reference	Relevance
" The possible importance of alpha-tocopherol in preventing the toxic effect of iron on the apparently very sensitive myocardium after parenteral iron to patients with severe malabsorption syndrome is discussed."	( Alpha-tocopherol and cardiac toxicity of iron. Lindvall, S; Rydén, L; Smedgärd, P; Swedberg, B, 1980)	0.26
" During the maintenance phase (period of epoetin therapy after correction of iron deficiency), the use of low-dose intravenous iron supplementation (10 to 20 mg per haemodialysis treatment or 100 mg every second week) avoids iron overtreatment and minimises potential adverse effects."	( Safety aspects of parenteral iron in patients with end-stage renal disease. Hörl, WH; Sunder-Plassmann, G, 1997)	0.3

Excerpt	Relevance	Reference
" Adequate intravenous iron supplementation allows reduction of epoetin dosage by approximately 40%."	( Safety aspects of parenteral iron in patients with end-stage renal disease. Hörl, WH; Sunder-Plassmann, G, 1997)	0.3

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	26 (70.27)	18.7374
1990's	7 (18.92)	18.2507
2000's	3 (8.11)	29.6817
2010's	1 (2.70)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (5.26%)	5.53%
Reviews	2 (5.26%)	6.00%
Case Studies	1 (2.63%)	4.05%
Observational	0 (0.00%)	0.25%
Other	33 (86.84%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
citric acid, anhydrous Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.	8.45	37	2	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	3.78	2	1	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	2.11	1	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).	8.45	37	2	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
thymidine [no description available]	1.99	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.11	1	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	3.43	1	1	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
copper gluconate Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.	1.93	1	0	organic molecular entity
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	1.95	1	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
plutonium Plutonium: A naturally radioactive element of the actinide metals series. It has the atomic symbol Pu, and atomic number 94. Plutonium is used as a nuclear fuel, to produce radioisotopes for research, in radionuclide batteries for pacemakers, and as the agent of fission in nuclear weapons.	1.96	1	0	actinoid atom; f-block element atom
ferrous sulfate ferrous sulfate: Ferro-Gradumet is ferrous sulfate in controlled release form; RN given refers to Fe(+2)[1:1] salt. iron(2+) sulfate (anhydrous) : A compound of iron and sulfate in which the ratio of iron(2+) to sulfate ions is 1:1. Various hydrates occur naturally - most commonly the heptahydrate, which loses water to form the tetrahydrate at 57degreeC and the monohydrate at 65degreeC.	1.93	1	0	iron molecular entity; metal sulfate	reducing agent
transferrin Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.	2.34	2	0
glucaric acid Glucaric Acid: A sugar acid derived from D-glucose in which both the aldehydic carbon atom and the carbon atom bearing the primary hydroxyl group are oxidized to carboxylic acid groups.. D-glucaric acid : The D-enantiomer of glucaric acid.. glucaric acid : A hexaric acid derived by oxidation of sugar such as glucose with nitric acid.	3.09	1	0	glucaric acid	antineoplastic agent
ferric citrate ferric citrate: RN given refers to Fe(+3)[1:1] salt. iron(III) citrate : An iron chelate resulting from the combination of iron(3+) and citrate(3-).	1.93	1	0	iron chelate	anti-anaemic agent; nutraceutical
fe(iii)-edta Fe(III)-EDTA: iron fortifying agent; RN given refers to parent cpd	3.43	1	1	iron coordination entity
4-hydroxy-2-nonenal 4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.	2.4	2	0	4-hydroxynon-2-enal; 4-hydroxynonenal
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	3.49	2	0
ferrous gluconate ferrous gluconate: iron important in this cpd; RN given refers to ferrous cpd	3.09	1	0
teferrol [no description available]	3.09	1	0
ferric oxide, saccharated Ferric Oxide, Saccharated: A glucaric acid-iron conjugate that is used in the treatment of IRON-DEFICIENCY ANEMIA, including in patients with chronic kidney disease, when oral iron therapy is ineffective or impractical.	3.09	1	0

Condition	Relationship Strength	Studies	Trials
Anemias, Iron-Deficiency [description not available]	5.35	5	1
Anemia, Iron-Deficiency Anemia characterized by decreased or absent iron stores, low serum iron concentration, low transferrin saturation, and low hemoglobin concentration or hematocrit value. The erythrocytes are hypochromic and microcytic and the iron binding capacity is increased.	5.35	5	1
Enlarged Liver [description not available]	2.01	1	0
Extravascular Hemolysis [description not available]	1.93	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	1.93	1	0
Anemia, Hypochromic Anemia characterized by a decrease in the ratio of the weight of hemoglobin to the volume of the erythrocyte, i.e., the mean corpuscular hemoglobin concentration is less than normal. The individual cells contain less hemoglobin than they could have under optimal conditions. Hypochromic anemia may be caused by iron deficiency from a low iron intake, diminished iron absorption, or excessive iron loss. It can also be caused by infections or other diseases, therapeutic drugs, lead poisoning, and other conditions. (Stedman, 25th ed; from Miale, Laboratory Medicine: Hematology, 6th ed, p393)	4.65	11	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	3.19	6	0
Complications, Pregnancy [description not available]	2.34	2	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	3.95	5	0
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	1.93	1	0
Hematuria Presence of blood in the urine.	1.93	1	0
Complications, Hematologic Pregnancy [description not available]	1.94	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.94	1	0
Anemia, Hemolytic, Acquired [description not available]	1.94	1	0
Addison's Anemia [description not available]	1.94	1	0
Anemia, Hemolytic A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).	1.94	1	0
Infection [description not available]	1.94	1	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	1.94	1	0
Polyarthritis [description not available]	1.94	1	0
Rheumatoid Arthritis [description not available]	1.94	1	0
Arthritis Acute or chronic inflammation of JOINTS.	1.94	1	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	1.94	1	0
Cicatrization The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.	1.96	1	0
E coli Infections [description not available]	2.38	2	0
Necrotizing Pyelonephritis [description not available]	2.38	2	0
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	1.96	1	0
Cicatrix The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.	1.96	1	0
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	2.38	2	0
Pyelonephritis Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.	2.38	2	0
Chronic Illness [description not available]	3.29	2	0
Acute Disease Disease having a short and relatively severe course.	2.87	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	3.29	2	0
Arrhythmia [description not available]	1.95	1	0
Malabsorption Syndromes General term for a group of MALNUTRITION syndromes caused by failure of normal INTESTINAL ABSORPTION of nutrients.	1.95	1	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	1.95	1	0
Granuloma, Hodgkin [description not available]	1.95	1	0
Innate Inflammatory Response [description not available]	1.95	1	0
Germinoblastoma [description not available]	1.95	1	0
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	1.95	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	1.95	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	1.95	1	0
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	1.95	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	1.98	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	3.37	1	1
Benign Neoplasms [description not available]	3.37	1	1
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	3.37	1	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.37	1	1
Chronic Kidney Failure [description not available]	2.91	1	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	2.91	1	0
Iron Overload An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)	2.91	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.99	1	0
Adjuvant Arthritis [description not available]	1.98	1	0
Plica Syndrome [description not available]	1.98	1	0
Synovitis Inflammation of the SYNOVIAL MEMBRANE.	1.98	1	0
Calcification, Pathologic [description not available]	1.97	1	0
Calciphylaxes [description not available]	1.97	1	0
Calcinosis Pathologic deposition of calcium salts in tissues.	1.97	1	0

citric acid, iron, sorbitol drug combination

Description

Cross-References

Synonyms (16)

Research Excerpts

Toxicity

Dosage Studied

Research

Studies (37)

Market Indicators

Research Demand Index: 10.33

Study Types

citric acid, iron, sorbitol drug combination

Description

Cross-References

Synonyms (16)

Research Excerpts

Toxicity

Dosage Studied

Research

Studies (37)

Market Indicators

Research Demand Index: 10.33

Study Types

Related Drugs (20)

Related Conditions (57)